Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

ConclusionsThe study results, including a pharmacokinetic profile consistent with weekly dosing and low incidence of immunogenicity, support further investigation of eftozanermin alfa.Trial registration ID: NCT03082209.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research